CLEC4E

Across TCGA pan-cancer cohorts, CLEC4E mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CLEC4E data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CLEC4E mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLEC4E expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC and PDAC are the cancer types where CLEC4E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	1.000	0.641	.013	6	view →
PDAC	OS	Median	All	0.462	0.880	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CLEC4E–LSCC (OS)

Open the LSCC breakdown →